Hint mode is switched on Switch off

Explore the most comprehensive database

1 000 000

bonds

80 234

stocks

167 970

ETF & Funds

70 000

indices

Track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Invivyd: On May 31, 2024, The Company Issued A Press Release Announcing General Alignment With The U.s. Food And Drug Administration On An Expedient, Repeatable Immunobridging Pathway To Future Potential Emergency Use Authorizations For Serial, Novel Monoclonal Antibodies For The Prevention And Treatment Of Symptomatic, Financial Statements And Exhibits

May 30, 2024 U.S. Securities and Exchange Commission
Show full article
This functionality is available for registred users only
Issuer — Invivyd
  • Full name
    Invivyd Inc
  • Registration country
    USA
  • Industry
    Pharmaceutical Preparation and Biotechnology
  • М/S&P/F
    *** / *** / ***

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Other Company's News

Try in 7-days Trial access

Free for company representative

  • Get full online access to the database
  • Use our powerful bond screener
  • Track bond prices from 400+ sources
  • Smart Portfolio Monitoring
  • Evaluate advanced analytical tools
Sign up

Why Cbonds?

  • 24 Years of Market Leadership
  • Trusted by clients across 90 countries for decades of reliable service
  • Used by Financial Professionals & Fintech central banks, asset managers, fintech innovators
  • Convenient platform for private investors for informed investment decisions
Registration is required to get access.